Radiolabeling of Zonisamide for a Diagnostic Perspective

Basit Öğe Kaydı
dc.authoridYURT KILCAR, AYFER/0000-0003-0866-7515
dc.authoridDurkan, Kubra/0000-0002-0783-8557
dc.authoridKARATAY, Kadriye Busra/0000-0002-2811-4689
dc.contributor.authorDervis, Emine
dc.contributor.authorKaratay, Kadriye Busra
dc.contributor.authorDurkan, Kubra
dc.contributor.authorKilcar, Ayfer Yurt
dc.date.accessioned2024-08-31T07:50:44Z
dc.date.available2024-08-31T07:50:44Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Epilepsy is one of the oldest and the most common chronic neurological diseases. Antiepileptic drugs (AEDs) are the backbone of epilepsy treatment. However, epileptogenesis has not been fully elucidated. One of the critical reasons for this is the lack of reliable biomarkers. Neuroimaging suggests a non-invasive examination and investigation tool that can detect critical pathophysiological changes involved in epileptogenesis and monitor disease progression. In the current study, the radiolabeling potential of Zonisamide (ZNS) (the secondgeneration AED) with Technetium-(99m) (Tc-99m) is examined to neuroimage the epileptogenic processes by contributing to the development of potential radiotracers. Methods: ZNS was labeled with Tc-99m and the radiochemical yield of [Tc-99m]Tc-ZNS was determined with TLRC (Thin Layer Liquid Radio Chromatography and HPLRC (High Performance Liquid Radio Chromatography) radiochromatographic methods. In vitro behavior of [Tc-99m]Tc-ZNS was determined with time-dependent uptake of [Tc-99m]Tc-ZNS on the SHSY5Y human neuroblastoma cells. Results: The radiochemical yield of [Tc-99m]Tc-ZNS was determined as 98.03 +/- 1.24% (n = 6) according to radiochromatographic studies results. [Tc-99m]Tc-ZNS demonstrated 5.38 and 6.18 times higher uptake values than the control group on the human neuroblastoma SH-SY5Y cell line at 120 and 240 minutes, respectively. Conclusion: This study showed that the current radiolabeled antiepileptic drug has a diagnostic potential to be used in imaging neurological processes.en_US
dc.identifier.doi10.2174/0118744710249156231002115024
dc.identifier.endpage98en_US
dc.identifier.issn1874-4710
dc.identifier.issn1874-4729
dc.identifier.issue1en_US
dc.identifier.pmid37818565en_US
dc.identifier.scopus2-s2.0-85190433064en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage91en_US
dc.identifier.urihttps://doi.org/10.2174/0118744710249156231002115024
dc.identifier.urihttps://hdl.handle.net/11454/105337
dc.identifier.volume17en_US
dc.identifier.wosWOS:001208284200005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectZonisamide (Zns)en_US
dc.subjectAntiepileptic Drugsen_US
dc.subjectEpilepsyen_US
dc.subjectTechnetium-99m (Tc-99m)en_US
dc.subjectNeuroimagingen_US
dc.subjectIn Vitroen_US
dc.titleRadiolabeling of Zonisamide for a Diagnostic Perspectiveen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu